MTOR and glioma: Even though ARL4D was previously identified as a glioma-associated antigen dependent on loss of PTEN and consequent activation of Akt/mTOR pathway [45, 46], its oncogenic roles and underlying molecular mechanisms have never been reported in any cancer type before.